Navigation Links
XTL Provides Update on Phase I Clinical Trial of XTL-2125

VALLEY COTTAGE, New York, June 06, 2007 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. announced today that it has completed the analysis of results from a Phase I clinical trial with XTL-2125 in patients with chronic Hepatitis C. This Phase I trial was a placebo controlled, randomized, dose escalating study, which evaluated the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125. The study enrolled 56 patients into seven cohorts comprised of eight patients each (of which two are placebo patients). Each patient received a single dose, followed by a 14-day multi-dosing regimen commencing one week after the single dose administration. The highest daily multi-dose regimen that was evaluated in the trial was 1800mg per day (600mg three times per day).

The analysis of the data indicates that XTL-2125 was generally well tolerated. However, HCV-RNA viral load reductions in patients treated with XTL-2125 were not significantly different from those observed in the placebo group. Based on these results, XTL has decided to suspend further development of XTL-2125.

XTL's CEO, Ron Bentsur, commented: "The completion of this Phase I trial concludes our research on the XTL legacy compounds that we inherited. Through an aggressive business development effort, XTL's new management team has successfully reinvented the company's product portfolio - with Bicifadine as a lead product in late stage clinical development, and the XTL-DOS program, which is emerging as a very promising program in Hepatitis C. We look forward to an exciting rest of 2007, with the initiation of a late-stage clinical trial with Bicifadine in chronic neuropathic pain, and the initiation of IND-enabling studies with a novel hepatitis C inhibitor from the XTL-DOS program. We will also continue to opportunistically seek to broaden our portfolio through the in-licensing and acquisitions of additional clinical
'"/>




Page: 1 2 3

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
3. Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls
4. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
5. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
8. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
9. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
10. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
11. NeoPharm Provides Update on LE-SN38 Program
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: XTL Provides Update Phase Clinical Trial XTL
(Date:7/29/2014)... -- Sequenom, Inc. (NASDAQ: SQNM ), a life ... total revenues of $39.8 million for the second quarter ... of $24.5 million for the second quarter of 2013. ... sold on May 30, 2014, has been accounted for ... been excluded from continuing operations for all periods. ...
(Date:7/29/2014)... GLENWOOD, Ill. , July 29, 2014  Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... will release financial results for the fiscal third quarter ... 2014. The Company will host a ... at 9:00 a.m. Central Time (10 a.m. Eastern Time). ...
(Date:7/29/2014)... July 29, 2014 According to ... "Surgical Navigation Systems Market (Neurosurgical Navigation Systems, ENT Navigation ... Size, Share, Growth, Trends and Forecast, 2014 - 2020", ... USD 218.5 million in 2013 and is expected to ... 2020, to reach an estimated value of USD 295.5 ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... (NASDAQ: THOR), a world leader in device-based mechanical circulatory ... said today it will be participating in the Oppenheimer ... 13. Taylor C. Harris, Senior Director of ... on the company, beginning at 10:15 a.m., Eastern Standard ...
... Dec. 9, 2011 Quest Diagnostics Incorporated (NYSE: ... testing, information and services, announced that Care360™, the company,s ... e-Prescribing software system by Black Book Rankings, a leading ... services and software industries. Black Book ...
Cached Medicine Technology:Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 2Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings 3
(Date:7/29/2014)... 29, 2014 Winter is here down ... afternoon in Sydney’s central business district. That is, until ... costume transformed the otherwise ordinary day into a celebration—a ... are ardent advocates of The Truth About Drugs, a ... Scientology . They woke up the city with a ...
(Date:7/29/2014)... DailyGossip.org reveals in its latest review that the new method ... patients and what they have to go through when cold ... of the new program. Ellie claims that she suffered from ... her very own research. Four years passed until she reached ... Get Rid of Cold Sores program claims that she was ...
(Date:7/29/2014)... Regardless of the good things that happen ... share those with. Love is about understanding, commitment and ... is also about overcoming all the challenges that a ... relationship, women need to know how to understand guys. ... program, please visit the official website at http://www.dailygossip.org/enchant-him-review-7111 ...
(Date:7/29/2014)... July 29, 2014 (HealthDay News) -- Want young children ... them something that,s healthy is good for them. Doing ... good, a new study suggests. "Parents and caregivers ... may be better off simply serving the food without ... yummy the food actually is," said study authors Michal ...
(Date:7/29/2014)... Advertising claims for cosmetic procedures using stem cells ... safety and effectiveness, according to a review in the ... , the official medical journal of the ... cells offer tremendous potential, but the marketplace is saturated ... patients at risk," write Dr Michael T. Longaker of ...
Breaking Medicine News(10 mins):Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Get Rid of Cold Sores Fast Review Exposes the Way to Stop Outbreaks 2Health News:How to Reach the Heart of the Perfect Guy with "Enchant Him Program" - a Report by Daily Gossip Magazine 2Health News:Kids Will Pass on 'Healthy' Foods 2Health News:Beware of claims about cosmetic stem cells procedures, says review in Plastic and Reconstructive Surgery 2
... ... Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for ... ... 10, 2010 -- An experimental thyroid drug reduces cholesterol without the troublesome side effects ...
... TUCSON, Ariz. , March 10 If ... of continuing medical education (CME) used by physicians will be ... dramatic increase over the 9% of CME delivered via the ... the winter, 2010 issue of the Journal of Continuing ...
... ... Registered Dietitian Day on March 10, the team behind Skinny in ... combining the best diet and nutrition information with the latest fashion ... ) online directory. Spearheaded by celebrity dietitian Tanya Zuckerbrot, M.S., ...
... ... ... -- A week from today, the Boston branch of the Harvard Business School Alumni ... co-founder Mike “Zappy” Zapolin will be in attendance to present the new website’s business ...
... ... ... ... ...
... may be able to safely lower the platelet ... patients without risking increased bleeding, according to new ... other medical institutions. Reducing platelet transfusions, and ... could help address frequent shortages in platelet supplies, ...
Cached Medicine News:Health News:Thyroid Hormone Analogue for Treating High Cholesterol 2Health News:Thyroid Hormone Analogue for Treating High Cholesterol 3Health News:Study Predicts Half of Physician Continuing Education Will Be Online by 2016 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 2Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 3Health News:New Interactive Dietitian Directory Launches on National Registered Dietitian Day: TheSkinnyonDietitians.com 4Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 2Health News:PrescriptionDrugs.com and Mike “Zappy” Zapolin Have Been Selected to Compete in Harvard Business School New Venture Contest 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 2Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 3Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 4Health News:Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting 5Health News:Fewer platelets could be used for some cancer and bone-marrow transplantation patients 2
... With a zoom ratio of ... 0.75X to 11.25X, and the ... intervals from 1X to 11X, ... Magnifications of 3.75X to 540X ...
Inquire...
... apochromatically corrected objectives for ... most exacting demands in ... suitable for visual field ... mm and feature sufficiently ...
... working distances with high Numerical Apertures, these ... optical aberrations throughout the visible spectrum from ... across the entire 25mm field of view. ... colour reproduction, plus resolving power at the ...
Medicine Products: